Tag: Cocrystal Pharma

Business

Cocrystal Pharma Inc. (NASDAQ: COCP) Announces the Completion of the IND-enabling Studies with CC-42344 and Reports on a Possible Phase 1 Trial

by 0 comments

There are more than 1 billion people infected with seasonal influenza annually in the US, according estimated by the World Health Organization (WHO). This translates to approximately 3 million to 5 million cases of severe illness. The situation has triggered the completion of IND-enabling studies for CC-42344 by Cocrystal Pharma […]

Continue Reading →
Business

Cocrystal Pharma Inc. (NASDAQ: COCP) Jumps 9% on Promising CDI-45205 Inhibitor Results against COVID-19 Variants

by 0 comments

Cocrystal Pharma Inc. (NASDAQ: COCP) jumped 9.6% after announcing that the company’s lead preclinical SARS-CoV-2 3CL proteases inhibitor CDI-45205 was actives against COVID-19 and two other common SARS-CoV-2 strains.  CDI-45205 demonstrated antiviral activity  In vitro studies assessing CDI-45205 antiviral activity and its analogs in VeroE6-eGFP cells infected with SARS-CoV-2 (Wuhan […]

Continue Reading →